Global /China /Healthcare /Drug Manufacturers - General /301301
chevron_leftBack
Yili Chuanning Biotechnology Co.,Ltd. logo

Yili Chuanning Biotechnology Co.,Ltd.

301301
SHE: 301301 Delayed
10.03CNY 2.8%
1.48 USD
As of 24 June 2026, Yili Chuanning Biotechnology Co.,Ltd. has a market cap of $3.21B USD, ranking #5175 globally and #1095 in China. It ranks #406 in the Healthcare sector, and #161 in the Drug Manufacturers - General industry.
Global Rank
5175
Country Rank
1095
Sector Rank
406
Industry Rank
161
Key Stats
Market Cap
$3.21BUSD
21.77B CNY
Enterprise Value
$3.3BUSD
22.35B CNY
Revenue (TTM)
$650.63MUSD
4.41B CNY
EBITDA (TTM)
$198.26MUSD
1.34B CNY
Net Income (TTM)
$87.19MUSD
591.52M CNY
EBITDA Margin
30%
Profit Margin
13%
PE Ratio
37.3
Forward PE
21.2
PS Ratio
4.9
PB Ratio
2.6
EV/EBITDA
16.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Xuheng Deng open_in_new
Employees
3,126
Founded
2010
Website
klcnsw.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
2.8% -3.5% -13% -12% -11% -19%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
301301
伊犁川宁生物技术股份有限公司 Ordinary Shares Class A
ISIN: CNE100005WX0
Shares Out.:
618.817M1 Shares Float: 522.619M2
TV:
SA:
YF:
GF:
BA:
MS:
10.03 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Yili Chuanning Biotechnology Co.,Ltd.

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ectoine, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop cultivation, detection, technical consultation, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.79B
364.89B CNY
2K%
44.9
603259
$49.58B
336.36B CNY
1K%
17.2
$28.5B
223.48B HKD
788%
35.7
$18.79B
147.32B HKD
486%
162.3
$16.49B
111.89B CNY
414%
-
9926
$16.0B
125.46B HKD
399%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
24K%
38.1
JNJ
$547.28B
17K%
26.4
ABBV
$360.63B
11K%
97.4
$316.71B
256.25B CHF
10K%
19.9
AZN
$285.49B
215.59B GBP
9K%
27.6
MRK
$274.03B
8K%
15.1
chevron_leftBack